The defining mechanism is an inherited enzyme defect affecting biochemical and metabolic pathways. The ten gene associations in this packet span multiple metabolic pathways: ABCA1 and APOC3 are involved in lipid transport; ASNS encodes asparagine synthetase; ATP6V0A4 and SLC4A4 are associated with acid-base regulation; CHST3 and SLC26A2 relate to sulfate transport; GK encodes glycerol kinase; PIGA is involved in glycosylphosphatidylinositol anchor biosynthesis; and BPNT2 encodes a bisphosphate nucleotidase. No inheritance pattern data are available for the umbrella category.

Diagnostic information is not available in this packet for inborn errors of metabolism as a category. The two linked GeneReviews chapters—Achondrogenesis Type 1B and SLC26A2-Related Atelosteogenesis—describe specific skeletal dysplasia subtypes and do not provide diagnostic criteria applicable to the broader category.

No approved treatments are listed in this packet for inborn errors of metabolism as an umbrella category. Three orphan drug designations are recorded for conditions within this classification.

Prognosis data are not available in this packet for inborn errors of metabolism as an umbrella category.

Ten clinical trials are active or recently recruiting for conditions within or related to inborn errors of metabolism. These include studies examining genetic diagnosis, metabolic screening (including blood spot and urine metabolomic screening), hematopoietic cell transplantation approaches for non-malignant metabolic disorders, and natural history studies characterizing the genomic and pharmacological landscape of affected populations.